Acute Myeloid Leukemia
Researchers from University of Naples report details of new studies and findings in the area of acute myeloid leukemia
Published in Stem Cell Week, February 9th, 2009
"A large proportion of adult patients with acute myeloid leukemia (AML) relapse after treatment, and some of them are resistant to primary induction chemotherapy. Sixty-one patients from seven hematological centers with poor-risk AML, primary refractory (n = 16), or relapsed (n = 45) were treated with a salvage regimen, including fludarabine (2 days) and cytarabine (3 days) in a sequential continuous infusion, associated with liposomal daunorubicin (3 days) (FLAD)," scientists writing in the journal Annals of Hematology report.
"Complete response rate was 44% and 56% for refractory and relapsed patients, respectively, with an overall response rate of 52% (32 of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
Source: Stem Cell Week (2009-02-09)
More Articles from Stem Cell Week
- New York University
Biologists find stem cell-like functions in other types of plant cells - Acute Myeloid Leukemia
Researchers at University of Washington have published new data on acute myeloid leukemia - Celgene Corporation
Celgene Reports Record Fourth Quarter and Full Year 2008 Product Sales and Operating Profits - Fibrin Tissue Adhesives
Study data from M.C. Tirindelli and colleagues update understanding of fibrin tissue adhesives - Life Sciences
New research on life sciences from Mayo Clinic summarized - Amyloidosis
New data from University of Paris illuminate research in amyloidosis - More from this issue of Stem Cell Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
